Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic. Atreca has set up its credentials through V...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.